Stryker Corporation

SYK

Medical - Devices · Healthcare

Also trades as: 0R2S.L · SYK.DE

Price

$329.45

+1.75 (+0.53%)

Market Cap

$126.30B

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Strong

Growth

Strong

Cash Flow

Exceptional

Stability

Strong

Valuation

Good

Dividends

Mixed

Track this stock — start free trial

Winston Score History

The full picture

Stryker makes medical equipment used in hospitals and surgery centers around the world. Its main products include artificial knees and hips, surgical robots, hospital beds, and trauma implants used to fix broken bones. It is one of the largest medical device companies in the world and owns the Mako surgical robot system, which is widely used in joint replacement surgeries.

Stryker earns money by selling its devices and implants directly to hospitals and surgeons, and it also generates recurring revenue from software, service contracts, and replacement parts tied to its installed equipment. The company operates in over 75 countries, with the United States making up the majority of its sales. Its competitive moat comes from deep relationships with surgeons, a broad product portfolio, and the high switching costs once hospitals adopt its systems. The key growth driver is the aging global population, which is expected to increase demand for joint replacement procedures over the coming decades.

Politician Trades

38 trades / 12mo

20 Congressional buys and 18 sells on SYK in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+9.4% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+43.1% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$1.6B/ year

↑ Rising (+12% vs prior year)

6.3% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

9.3%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$3.5B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Stryker Corporation is growing revenue at 9% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

−0.0% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 382.3M (2021) → 382.2M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

68.3%

Premium pricing power — 68.3% gross margin

Profit after running costs

Operating Margin

25.2%

Excellent — 25.2% operating margin

Return on the money invested

ROCE

14.6%

Good — 14.6% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+8.5%

Steady sales growth (+8.5% YoY)

Profit growth

EPS YoY

+27.2%

Earnings growing fast (+27.2% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

148%

Turns 148% of profit into real cash

Spare cash per sale

FCF Margin

18.2%

Converts sales into free cash efficiently (18.2%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.62

Moderate — manageable debt (0.62)

Covers its interest

Interest Cover

8.30x

Comfortably covers interest (8.3x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

33.9x

Pricey — P/E 33.9

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year

P/E vs Forward

+15.8

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (33.9 → 18.1)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

1.03%

Small dividend — 1.03% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

+4.8%

Dividend growing modestly (4.8% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial